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After this activity the reader will be able to:
•  Describe the geographic distribution of cases of 
Streptococcus pyogenes infection.
•  Describe demographic proﬁ  le of patients with S. pyogenes 
infection.
•  Describe seasonal patterns of S. pyogenes infection.
•  Describe the clinical presentation of patients with S. 
pyogenes infection.
•  List 4 risk factors for S. pyogenes infection.
•  List 4 potential public health actions for minimizing the effects 
of S. pyogenes infection. 
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al Public Health Institute, Helsinki, FinlandAs part of a Europe-wide initiative to explore current 
epidemiologic patterns of severe disease caused by Strep-
tococcus pyogenes, the United Kingdom undertook en-
hanced population-based surveillance during 2003–2004. A 
total of 3,775 conﬁ  rmed cases of severe S. pyogenes infec-
tion were identiﬁ  ed over 2 years, 3.33/100,000 population, 
substantially more than previously estimated. Skin/soft tis-
sue infections were the most common manifestation (42%), 
followed by respiratory tract infections (17%). Injection drug 
use was identiﬁ  ed as a risk factor for 20% of case-patients. 
One in 5 infected case-patients died within 7 days of di-
agnosis; the highest mortality rate was for cases of necro-
tizing fasciitis (34%). Nonsteroidal antiinﬂ  ammatory drugs, 
alcoholism, young age, and infection with emm/M3 types 
were independently associated with increased risk for strep-
tococcal toxic shock syndrome. Understanding the pattern 
of these diseases and predictors of poor patient outcome 
will help with identiﬁ  cation and assessment of the potential 
effect of targeted interventions.
D
iseases caused by the Lanceﬁ  eld group A streptococ-
cus Streptococcus pyogenes are among the most var-
ied in terms of clinical spectra and severity, ranging from 
the ubiquitous pharyngitis to rarer life-threatening mani-
festations such as necrotizing fasciitis. Interest in these 
diseases was renewed after the United States and several 
countries in Europe reported increasing numbers of cases 
of invasive S. pyogenes disease during and since the 1980s 
(1). These apparent changes triggered several rapid global 
initiatives, coordinated by a World Health Organization 
working group, including review of microbiologic diagnos-
tic methods and commencement of enhanced surveillance 
in several countries during the mid-1990s (2).
In light of these changes, a cohesive network of 11 
countries was formed in September 2002 to gain insight 
into the epidemiology of severe S. pyogenes disease across 
Europe. This network was funded by the European Union 
Fifth Framework Programme (3). To meet the Strep-EURO 
program objectives, the United Kingdom and other coun-
tries established population-based enhanced surveillance of 
severe S. pyogenes disease. Surveillance was undertaken 
to obtain accurate and comparable measures of overall 
and disease-speciﬁ  c incidence among participants and to 
compare demographic, risk factor, and clinical proﬁ  les of 
case-patients between countries, as well as microbiologic 
characteristics of S. pyogenes isolates collected.
Methods
In accordance with the program objectives, the Public 
Health Laboratory Service (now part of the Health Protec-
tion Agency) initiated enhanced surveillance of severe S. 
pyogenes disease from January 1, 2003, through December 
31, 2004. Cases were deﬁ  ned according to the US deﬁ  ni-
tion (S. pyogenes isolated from a sterile site) (4). Also in-
cluded were cases in which S. pyogenes was isolated from 
a nonsterile site in combination with probable streptococcal 
toxic shock syndrome (STSS) or another severe manifes-
tation (pneumonia, necrotizing fasciitis, puerperal sepsis, 
meningitis, or septic arthritis). STSS was deﬁ  ned according 
to US speciﬁ  cations that differentiate between conﬁ  rmed 
and probable cases on the basis of recovery of a sterile or 
nonsterile site isolate, respectively (4).
To maximize case ascertainment, cases were identiﬁ  ed 
from 2 sources: isolate referrals to the national reference 
laboratory (Streptococcus and Diphtheria Reference Unit 
[SDRU]) and surveillance reports made to the Communi-
cable Disease Surveillance Centre (CDSC) (5). SDRU pro-
Severe Streptococcus pyogenes 
Infections, United Kingdom, 
2003–2004 
Theresa L. Lamagni,* Shona Neal,* Catherine Keshishian,* Neelam Alhaddad,* Robert George,* 
Georgia Duckworth,* Jaana Vuopio-Varkila,† and Androulla Efstratiou*
RESEARCH
202  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 2, February 2008
*Health Protection Agency, London, United Kingdom; and †Nation-
al Public Health Institute, Helsinki, FinlandSevere S. pyogenes Infections, UK, 2003–2004
vides reference microbiology services to the United King-
dom; CDSC surveillance covers England, Wales, Northern 
Ireland, the Channel Islands, and the Isle of Man. Cases 
identiﬁ   ed from each source were reconciled with each 
other by using automated techniques to match records on 
the basis of personal identiﬁ  ers (date of birth, sex, hospi-
tal number, National Health Service number, SOUNDEX-
coded surname) and geographic location, followed by loose 
matching and manual checking to allow records to differ 
slightly on any given matching parameter. Referring labo-
ratories were sent a study questionnaire to obtain further 
information on the demographic proﬁ  le of the patient, dis-
ease manifestations, markers of clinical severity, outcome, 
and possible sources of infection (6). Ethnicity of patients 
was sought and classiﬁ  ed according to census groupings 
for rate calculation. Where an isolate had not been received 
by SDRU, this isolate was also requested.
Group A streptococcal isolates referred to SDRU were 
characterized according to their M protein by using conven-
tional serologic and emm gene typing (7,8). Antimicrobial 
drug–susceptibility testing was conducted by referral labo-
ratories according to local standard operating procedures.
Responses to completed questionnaires were entered 
and stored in a custom-made Access (Microsoft, Redmond, 
WA, USA) database. All reports were checked to ensure 
they met the case deﬁ   nition. Repeat episodes were de-
ﬁ  ned as those occurring in the same patient >30 days after 
the initial episode; reports received within 30 days were 
considered part of the same episode. Data were extracted 
for statistical analysis into STATA statistical software re-
lease 8.2 (Stata Corporation, College Station, TX, USA). 
Descriptive statistics were undertaken on conﬁ  rmed cases 
with χ2 and t tests used to test statistical signiﬁ  cance of dif-
ferences between subgroups. Incidence rates were calculat-
ed by using midyear resident population estimates for the 
respective years, age groups, sexes, and regional popula-
tions, with exact 95% conﬁ  dence intervals (CIs) calculated 
according to the Poisson distribution. The 2001 census data 
were used as denominators for calculating rates according 
to ethnic group. All denominators were obtained from the 
Ofﬁ  ce for National Statistics. Stepwise unconditional lo-
gistic regression analysis was conducted to examine the 
independence of explanatory variables and development of 
STSS; the likelihood ratio test was used to evaluate signiﬁ  -
cance of explanatory variables within each model.
All analyses were made on data from the United King-
dom, Channel Islands, and Isle of Man, except for estimated 
rates of infection, which were calculated for the areas with 
dual reporting (England, Wales, Northern Ireland, Channel 
Islands, and Isle of Man). The last 2 areas were omitted for 
age-, sex-, and ethnicity-speciﬁ  c rate calculations because 
of unavailability of these population denominators.
Results
Overview of Surveillance Results
From January 1, 2003, through December 31, 2004, a 
total of 3,821 cases of severe S. pyogenes disease meeting 
the case deﬁ  nition were reported from laboratories across 
the United Kingdom, Channel Islands, and Isle of Man. 
Of these cases, 21% were identiﬁ  ed from isolate referrals 
only, without a corresponding surveillance report. Among 
the 3,821 reports were 46 repeat episodes, 5 of which 
were third episodes. Excluding repeat episodes, severe S. 
pyogenes disease was diagnosed for 3,775 patients in the 
United Kingdom, Channel Islands, and Isle of Man in 2003 
and 2004.
S. pyogenes was isolated from a sterile site from 3,742 
(99%) case-patients, primarily from blood culture (89%, 
3,352). Thirty-three cases without sterile site isolates were 
included on the basis of >1 of the following clinical indica-
tors: probable toxic shock syndrome (13 cases), necrotizing 
fasciitis (15), pneumonia (4), and puerperal sepsis (3).
Questionnaires were received for 2,647 (70%) of 
3,775 case-patients. Information available for case-patients 
for whom questionnaires were or were not returned indi-
cated their similarity in terms of age (median age 48 and 
45 years, respectively), sex (54% male for both), and strain 
characteristics (emm/M type and erythromycin resistance), 
although a slightly higher proportion of case-patients for 
whom a questionnaire was returned had disease onset in 
December–April (53% vs. 48%; χ2 6.37, degrees of free-
dom [df] 1, p = 0.012).
Geographic Distribution of Cases
In 2003 and 2004 combined, the overall rate of se-
vere S. pyogenes infections was 3.33/100,000 population 
for England, Wales, Northern Ireland, Channel Islands, 
and Isle of Man. Variations were seen across these coun-
tries, with report rates higher in England (3,413 cases, 
3.41/100,000) than Wales (153 cases, 2.60/100,000, rate 
ratio [RR] 1.32, 95% CI 1.12–1.55) or Northern Ireland 
(72 cases, 2.11/100,000, RR 1.62, 95% CI 1.28–2.04) but 
not signiﬁ  cantly higher than rates in the Channel Islands 
and Isle of Man (10 cases, 1.98/100,000, RR 1.55, 95% CI 
0.83–2.88). Substantial variations were also apparent be-
tween the English regions, with rates higher in Yorkshire 
and Humber (4.92/100,000) than in any other English re-
gion: East Midlands (3.25), East of England (2.98), London 
(2.75), North East (3.66), North West (3.70), South East 
(2.79), South West (3.92), and West Midlands (3.51). Re-
port rates decreased in 2004 (1,718 cases, 3.12/100,000, 
RR 0.89, 95% CI 0.83–0.95) compared with 2003 (1,930 
cases, 3.53/100,000); decreases in Yorkshire and Humber, 
and London accounted for 85% of this decrease.
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Demographic Proﬁ  le of Case-Patients
Severe  S. pyogenes infection reports were highly 
concentrated in elderly persons (>75 years of age, 10.67/
100,000) and the young (<1 years of age, 9.70/100,000) 
(Figure 1). Rates for male patients were 22% higher than 
for female patients (3.65/100,000 vs. 2.98/100,000, RR 
1.22; 95% CI 1.14–1.30); more male case-patients were 
found across all age groups, in particular, young adults 
(15–44 years of age), for whom rates were 61% higher for 
male than female patients (3.44/100,000 vs. 2.14/100,000, 
RR 1.61, 95% CI 1.43–1.80). Of 1,822 case-patients whose 
ethnicity was recorded, 1,727 (95%) were white, 58 (3%) 
from the Indian subcontinent, and 21 (1%) black African or 
Caribbean. Rates of severe S. pyogenes disease observed 
were signiﬁ  cantly higher for whites (3.29) than for those of 
Indian subcontinent (2.46/100,000, RR 1.34, 95% CI 1.02–
1.74) or black African or Caribbean origin (1.84/100,000, 
RR 1.79, 95% CI 1.16–2.75).
Seasonal Patterns of Infection
Marked seasonal peaks of severe S. pyogenes infec-
tion were observed in both years. Cases gradually increased 
from the end of October and ﬁ  rst peaked near the end of 
January (2nd week of 2003, 51 cases; 4th week of 2004, 
60 cases) before peaking again (higher) toward the end of 
March (12th week of 2003, 62 cases; 14th week of 2004, 
64 cases) (Figure 2).
Clinical Manifestations of Cases
Clinical information was reported on the study question-
naire for 2,611 (69%) severe cases of S. pyogenes infection 
(Table 1). Approximately one ﬁ  fth of patients were bactere-
mic but had no deﬁ  ned focus for infection. Of the remain-
der, skin/soft tissue was the most common focus of infection 
(42%, 1,099). Cellulitis was the most common manifesta-
tion, diagnosed for 881 (34%) patients; necrotizing fasciitis 
was diagnosed for 136 (5%) patients. Necrotizing fasciitis 
was rarely reported for pediatric case-patients (<16 years of 
age, 1%); most (64%, 87/136) cases occurred in persons 16–
60 years of age. The respiratory tract was the next most com-
monly affected system; 434 (17%) patients showed clinical 
signs of upper or lower respiratory tract infection. Pneumo-
nia was diagnosed for 309 (12%) case-patients.
Conﬁ  rmed STSS developed in 196 (8%) patients who 
had a diagnosis of severe S. pyogenes infection (Table 2); 
28% of these patients had necrotizing fasciitis. STSS de-
veloped in 40% (55/136) of patients with necrotizing fas-
ciitis compared with 6% of other patients (χ2 224.14, df 1, 
p<0.001). Use of nonsteroidal antiinﬂ  ammatory drugs was 
positively associated with development of STSS (22% vs. 
8%, χ2 13.71, df 1, p<0.001).
Multivariable analysis of patient, clinical, and microbi-
ologic factors associated with development of STSS identi-
ﬁ  ed age to be a strong predictor for STSS; risk for STSS 
was 5-fold greater for persons 15–44 years of age (odds 
ratio [OR] 5.42, 95% CI 2.22–13.23, p<0.001) than for the 
reference group (children <15 years of age). Persons 45–64 
years of age had a 5-fold increased risk for STSS (OR 5.20, 
95% CI 2.12–12.74, p<0.001). Patients >65 years of age 
had no increased risk for STSS compared with the pediatric 
reference group. Regardless of age, patients with necrotiz-
ing fasciitis had a 7-fold increased risk for STSS (OR 6.87, 
95% CI 4.25–11.09, p<0.001). 
Four risk factors (alcoholism, injection drug use, ma-
lignancy, and use of nonsteroidal antiinﬂ  ammatory drugs) 
were independently associated with development of STSS.   
Patients who used nonsteroidal antiinﬂ  ammatory  drugs 
had a 3-fold increased risk for STSS (OR 3.00, 95% CI 
1.30–6.93, p = 0.01). Alcoholism was associated with a 2-
fold increased risk for STSS (OR 2.52, 95% CI 1.27–5.03, 
p = 0.008). Conversely, patients with malignancies had a 
much lower risk for STSS (OR 0.34, 95% CI 0.12–0.96, 
p = 0.042), as did injection drug users (OR 0.23, 95% CI 
0.10–0.56, p = 0.001). Patients infected with an emm/M3 
type, which was the only strain associated with STSS, had 
a 3-fold increased risk for STSS compared with patients in-
fected with the reference group (emm/R28) (OR 3.20, 95% 
CI 1.35–7.58, p = 0.008).
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Figure 1. Age- and sex-speciﬁ   c annual incidence of severe 
Streptococcus pyogenes infection in England, Wales, and Northern 
Ireland, 2003–2004. Error bars show 95% conﬁ  dence intervals.
Figure 2. Seasonal trends in reports of severe Streptococcus 
pyogenes infection in the United Kingdom, 2003–2004. Moving 
average (6 wk) is the average count for the previous 6 weeks.Severe S. pyogenes Infections, UK, 2003–2004
Overall, 413 (19%) patients for whom S. pyogenes 
infection was the main underlying or contributory cause 
of death died within 7 days of initial microbiologic diag-
nosis. Necrotizing fasciitis was the most severe clinical 
manifestation for patients, according to speciﬁ  ed mark-
ers; patients with this condition were most likely to be 
admitted to an intensive care unit (ICU) (77%) or to die 
within 7 days of diagnosis (34%). However, ICU admis-
sion (20%) and surgical intervention (24%) were not un-
common among other patients. Case-fatality rates were 
also high for patients with pneumonia, 32% of whom died 
within 7 days. Of the 58 young women in whom puer-
peral sepsis developed, 2 died. Development of STSS was 
strongly linked to risk for death; 84 (45%) of 185 patients 
with STSS died from their infection compared with 329 
(16%) of 2,007 without STSS.
Patient Risk Factors
Information on risk factors was available for 61% 
of case-patients with severe S.  pyogenes infection. Of 
these, lesions or wounds to the skin were reported for 
31% (719). Skin is the most likely portal of entry record-
ed overall, especially among persons >60 years of age, 
40% of whom had skin lesions. Information on the na-
ture of these lesions was available for 617 case-patients. 
The 2 most common types were traumatic lesions (188) 
and chronic wounds (161). Traumatic lesions were most 
common among young adults (16–60 years of age, 9%); 
chronic wounds were most common among elderly per-
sons (14%). Less common types of wounds were recorded 
that included insect bites (21 cases, 0.9%) and animal-
associated traumatic wounds (cat scratches and dog and 
human bites, 8 cases, 0.3%).
Of young adults with severe S. pyogenes infections, 
459 (40%) were injection drug users (20% of case-patients 
of all ages). Other conditions commonly reported that could 
have predisposed persons to infection included malignan-
cies (161) and diabetes (158), each noted for 7% of cases 
overall and 11% and 13%, respectively, among elderly per-
sons. Nine percent (204) of infections were associated with 
healthcare, mostly postsurgical infections (118). Among 
pediatric case-patients (<16 years of age), varicella was the 
next most common predisposing factor noted after skin le-
sions, reported for 41 (14%) children. Overall, 566 (25%) 
case-patients did not have any particular predisposition, or 
risk for severe S. pyogenes infection on the basis of the 
common factors outlined (Table 3) or any others consid-
ered pertinent by the reporting clinician. Among pediatric 
case-patients, this proportion increased to 46% (132).
Discussion
As part of a wider European initiative to improve our 
understanding of the epidemiology of severe S. pyogenes 
infections, the United Kingdom has amassed one of the 
largest collections of such cases recorded. The >3,700 cases 
diagnosed in 2003–2004 resulted in a rate of 3.33/100,000 
population for England, Wales, Northern Ireland, the Chan-
nel Islands, and Isle of Man. This rate was similar to rates 
reported for other European countries and the United States 
in the early 2000s (1,9,10), although lower than some esti-
mates from Canada (11–13). In the 2-year study period, the 
overall rate of severe S. pyogenes infections decreased from 
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Table 1. Clinical manifestations of severe Streptococcus pyogenes infection, United Kingdom, 2003–2004 
Manifestation
All case-patients,  
no. (%)* 
Children <16 y of 
age, no. (%) 
Adults 16–60 y of 
age, no. (%) 
Adults >60 y of age, 
no. (%) 
Skin/soft tissue infection  1,099 (42)  85 (27)  479 (39)  531 (50) 
  Cellulitis  881 (34)  59 (19)  362 (30)  457 (43) 
  Necrotizing fasciitis  136 (5)  4 (1)  87 (7)  45 (4) 
  Abscess  134 (5)  6 (2)  112 (9)  16 (2) 
  Erysipelas  24 (1)  2 (1)  9 (1)  13 (1) 
Bacteremia with no defined focus  558 (21)  77 (24)  228 (19)  252 (24) 
Respiratory tract infection  434 (17)  66 (21)  187 (15)  181 (17) 
  Pneumonia  309 (12)  27 (8)  139 (11)  143 (13) 
Other lower respiratory tract infection  62 (2)  6 (2)  26 (2)  30 (3) 
  Pharyngitis/tonsillitis  51 (2)  26 (8)  16 (1)  9 (1) 
  Ear infection  22 (1)  8 (3)  9 (1)  5 (<1) 
  Epiglottitis  17 (1)  2 (1)  10 (1)  5 (<1) 
  Sinusitis  6 (<1)  4 (1)  0 2 (<1) 
Septic arthritis  220 (8)  40 (13)  114 (9)  66 (6) 
Puerperal sepsis  58 (2)  0 58 (5)  0
Acute abdominal infection†  49 (2)  5 (2)  31 (3)  12 (1) 
Cardiac infection‡  48 (2)  2 (1)  36 (3)  10 (1) 
Meningitis 37 (1)  18 (6)  12 (1)  7 (1) 
Total 2,611 (100)  318 (100)  1,225 (100)  1,064 (100) 
*Includes patients without age information.  
†Includes 14 patients with peritonitis, 1 with appendicitis, and 1 with pancreatitis. 
‡Includes 42 patients with endocarditis, 4  with pericarditis, 1 with myocarditis, 1 with myocarditis and pericarditis. RESEARCH
3.53/100,000 to 3.12/100,000. This overall decrease was 
largely caused by a substantial decrease in 2 regions, York-
shire and Humber, and London. Use of multiple sources for 
case ascertainment was an improvement over previously 
used methods. Previous methods, which relied solely on 
voluntary laboratory reporting, would have yielded a rate 
of 2.65/100,000 during this period. As with any study de-
pendent on participation of local reporters, this study may 
have missed additional diagnosed cases.
Rates of severe diseases associated with S.  pyo-
genes were markedly higher in male patients than in fe-
male patients, an observation not consistently found in 
other countries (12,14) but commonly found among pa-
tients with bacteremic infections in the United Kingdom 
(15,16). We did not observe any increased rate of severe 
S. pyogenes infections in black patients of African or Ca-
ribbean origin, as was found in a large study in the United 
States (17). Estimated rates were lower for black patients 
than for Asian or white patients. Because our study relied 
on clinician and microbiologist reporting of ethnicity, the 
proportion of patients reported as white may have been 
overestimated as a result of assumptions made without 
conﬁ  rmatory information.
Marked seasonal patterns in severe S. pyogenes dis-
ease were evident during the study period, with an initial 
peak in December–January, followed by a strong peak 
in March–April. Preliminary comparisons among Strep-
EURO participants suggest similar patterns in other Euro-
pean countries (18). Why these diseases should peak in late 
winter and early spring is not known. Seasonal patterns of 
viral respiratory infections with respiratory syncytial virus 
and inﬂ  uenza virus, which could make patients vulnerable 
to invasive S. pyogenes infections, may play a role in early- 
to mid-winter S. pyogenes peaks but would not explain the 
main spring peak seen in the United Kingdom (Health Pro-
tection Agency, unpub. data).
Clinical information provided for these case-patients 
highlights the severity of these infections; 19% died within 
7 days of the initial culture-positive specimen being ob-
tained. This ﬁ  nding is consistent with overall case-fatal-
ity estimates during enhanced surveillance in the United 
Kingdom in 1994–1997 (25%) and estimates reported in 
other countries (14,17,19,20). However, only 1 of these 
studies deﬁ  ned a time frame for estimates or included the 
role of infection in the patient’s death, as our study did. 
Case-fatality rates were particularly high for case-patients 
with necrotizing fasciitis, who accounted for only 5% of all 
cases but 10% of all deaths. Completion of the question-
naire could also have been biased in favor of more severe 
or interesting cases.
Among case-patients identiﬁ  ed in this study, 12% had 
pneumonia, a value substantially higher than that noted by 
enhanced surveillance in the United Kingdom in 1994–
1997 (5%) (20). However, our ﬁ  nding was consistent with 
those in studies in other countries (11,13,17,19,21,22). The 
case-fatality rate in our study (32% within 7 days of initial 
diagnosis) was substantially higher than that expected with 
community-acquired pneumonia (23).
STSS developed in 8% of the case-patients identiﬁ  ed 
in our study. These patients had poor survival rates; 45% 
died within a week of initial diagnosis. STSS was most 
likely to develop in young adults, which is consistent with 
ﬁ  ndings of a US study that reported a lower median age for 
STSS patients (24). Infection with an emm/M3 strain was 
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Table 2. Clinical markers of severe Streptococcus pyogenes infection in the United Kingdom, 2003–2004* 
Marker
All case-
patients
(n = 2,611),  
no. (%) 
Bacteremia with 
no defined focus 
(n = 558), no. (%) 
Pneumonia
(n = 309), 
no. (%)  
Cellulitis (n = 
881), no. (%)
Septic
arthritis (n = 
220), no. (%) 
Necrotizing
fasciitis (n = 
136), no. (%) 
Puerperal
sepsis (n = 
58), no. (%) 
Clinical severity (n = 2,611) 
Hypotensive shock  494 (19)  101 (18)  70 (23)  155 (18)  43 (20)  80 (59)  13 (22) 
STSS (hypotension +  
>2 listed below) 
196 (8)  28 (5)  27 (9)  63 (7)  18 (8)  55 (40)  3 (5) 
  Renal impairment  381 (15)  69 (12)  50 (16)  149 (17)  40 (18)  58 (43)  3 (5) 
  Respiratory distress  288 (11)  41 (7)  113 (37)  67 (8)  20 (9)  33 (24)  1 (2) 
  Erythematous rash  231 (9)  30 (5)  15 (5)  135 (15)  13 (6)  17 (13)  4 (7) 
  Soft-tissue necrosis  254 (10)  0 8 (3)  116 (13)  13 (6)  136 (100)  3 (5) 
  Liver abnormality  185 (7)  31 (6)  23 (7)  65 (7)  14 (6)  31 (23)  3 (5) 
 Disseminated   
 intravascular   
 coagulation 
131 (5)  21 (4)  14 (5)  40 (5)  10 (5)  35 (26)  6 (10) 
Admission to ICU
(n = 2,292) 
451 (20)  76 (16)  68 (24)  136 (17)  40 (21)  101 (77)  8 (16) 
Surgical intervention
(n = 1,885) 
443 (24)  21 (6)  19 (8)  131 (20)  106 (63)  106 (87)  10 (24) 
Death within 7 d  
(n = 2,192) 
413 (19)  97 (22)  87 (32)  121 (16)  17 (9)  43 (34)  2 (4) 
*STSS, streptococcal toxic shock syndrome; ICU, intensive care unit. Severe S. pyogenes Infections, UK, 2003–2004
associated with an increased risk for STSS. This ﬁ  nding 
is consistent with previous (unadjusted) ﬁ  ndings from the 
United States (17) but different from ﬁ  ndings from Canada, 
which only identiﬁ  ed emm/M9, a strain uncommon in the 
United Kingdom, as associated with STSS (13). Alcohol-
ism was associated with increased risk for STSS; this as-
sociation was also found in other studies (13,22). However, 
risk for STSS was 3-fold greater for patients who were re-
ported to have used nonsteroidal antiinﬂ  ammatory drugs, 
despite adjustment for whether patients had necrotizing 
fasciitis, which is strongly associated with STSS. Because 
no data were collected about time, dose, indications for 
use, or which agent was taken, a causal link between use 
of nonsteroidal antiinﬂ  ammatory drugs and STSS cannot 
be inferred from our ﬁ  ndings. A confounding factor, such 
as delay in receiving appropriate treatment, which we did 
not adjust for in our analysis, could explain this ﬁ  nding. Pa-
tients who took nonsteroidal antiinﬂ  ammatory drugs may 
have had early signs, such as extreme pain, which indicated 
a more severe infection. Nonetheless, this remains an in-
teresting and potentially important observation in a contro-
versial area where evidence supporting either immunologic 
impairment or augmentation caused by nonsteroidal anti-
inﬂ  ammatory drugs remains unresolved (25). Other novel 
associations with STSS were made; e.g., STSS was less 
likely to develop in injection drug users or patients with 
malignancies than in other patients. These ﬁ  ndings point to 
immunocompetence as a necessary mediator for develop-
ment of STSS.
Questionnaires concerning possible predisposing fac-
tors have highlighted skin lesions as the most commonly 
identiﬁ  ed potential source of infection, which is similar to 
ﬁ  ndings in other countries (18,22). However, given the oc-
cult nature of S. pyogenes infections, as indicated by the 
high proportion (21%) of cases with no identiﬁ  ed focus, 
several of these cases may have originated from respiratory 
tract colonization. This colonization could lead to transient 
bacteremia, which in turn seeded local tissue sites, possibly 
in the presence of local trauma.
In contrast to preliminary ﬁ  ndings from other Strep-
EURO participants (18), a substantial proportion of case-
patients were injection drug users (20% overall and 40% 
among young adults). Regional breakdowns of risk factors 
were not undertaken in our analyses. However, regional 
differences in report rates are in part explainable by injec-
tion drug use–related cases, with highest overall rates in the 
Yorkshire and Humber region. This region had been identi-
ﬁ  ed as having a particular problem of severe S. pyogenes 
disease in injection drug users (26). Patterns of isolate re-
ferrals to the national reference laboratory over the past de-
cade suggest an increase in severe S. pyogenes infection in 
injection drug users (27). The reasons behind this change 
remain unclear and warrant further investigation.
Most severe S. pyogenes cases in our study occurred 
sporadically in the community; only 9% were associated 
with healthcare interventions. One fourth of all case-pa-
tients and nearly 1 in 6 young adults had no particular risk 
factors identiﬁ  ed. These ﬁ  ndings highlight the likely eco-
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Table 3. Potential predisposing factors for severe Streptococcus pyogenes infection, United Kingdom, 2003–2004 
Factor 
All case-patients,  
no (%)* 
Children <16 y of 
age, no. (%) 
Adults 16–60 y of 
age, no. (%) 
Adults >60 y of 
age, no. (%) 
Skin lesion/wound  719 (31)  63 (22)  298 (26)  358 (40) 
  Trauma  188 (8)  13 (5)  99 (9)  76 (9) 
  Chronic wound  161 (7)  0 39 (3)  122 (14) 
  Surgery  118 (5)  10 (4)  48 (4)  60 (7) 
Injection drug use  459 (20)  0 459 (40)  0
Healthcare-associated infection  204 (9)  15 (5)  79 (7)  109 (12) 
Malignancy  161 (7)  11 (4)  49 (4)  100 (11) 
Diabetes 158 (7)  3 (1)  40 (4)  115 (13) 
Alcoholism 88 (4)  0 67 (6)  21 (2) 
Recent childbirth  86 (4)  0 86 (8)  0
Steroid use  77 (3)  3 (1)  35 (3)  39 (4) 
Contact with person with S. pyogenes
infection† 57 (4)  7 (4)  34 (5)  16 (2) 
Nonsteroidal antiinflammatory drug use  49 (2)  3 (1)  18 (2)  28 (3) 
Varicella 47 (2)  41 (14)  4 (<1)  2 (<1) 
Cardiovascular disease  45 (2)  3 (1)  9 (1)  33 (4) 
Upper respiratory tract infection  39 (2)  9 (3)  24 (2)  6 (1) 
Renal impairment  31 (1)  2 (1)  19 (2)  10 (1) 
Other reported risk factor‡  112 (5)  30 (11)  41(4) 41 (5) 
No risk factors reported  566 (25)  132 (46)  173 (15)  260 (29) 
Total 2,305 (100)  284 (100)  1,135 (100)  884 (100) 
*Includes patients without age information. 
†Information available for 1,586 patients. 
‡Noted for <30 patients. RESEARCH
nomic effect of these infections and the challenges in de-
veloping any effective prevention measure.
Analysis of information collected in this study has 
yielded some unique insights into these infections and has 
begun to provide an evidence base for mounting public 
health initiatives in the United Kingdom (28). High and rap-
idly ensuing mortality rates among these patients emphasize 
the need for early recognition and rapid treatment. Main-
taining a high index of suspicion, especially where there are 
signs of possible necrotizing fasciitis, could clearly be life-
saving. Further analysis of emm/M type distribution, a key 
virulence factor inducing immunologic memory, will assist 
in assessment of the potential effect of vaccines currently 
under development. Changes in the epidemiology of severe 
S. pyogenes infections since the last period of enhanced sur-
veillance in the mid-1990s underline the need for periodic 
monitoring to detect changes in disease manifestations, risk 
groups, and microbiologic characteristics to develop strate-
gies for control and management of these infections.
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